The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A

Blood

Volumn 117, Issue 23, 2011, Pages 6326-6337

  Flick, Matthew J ^a   Chauhan, Anil K ^b   Frederick, Malinda ^a   Talmage, Kathryn E ^a   Kombrinck, Keith W ^a   Miller, Whitney ^a   Mullins, Eric S ^a   Palumbo, Joseph S ^a   Zheng, Xunzhen ^c   Esmon, Naomi L ^c   Esmon, Charles T ^c,d   Thornton, Sherry ^a   Becker, Ann ^a   Pelc, Leslie A ^e   Di Cera, Enrico ^e   Wagner, Denisa D ^b   Degen, Jay L ^a,f  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 11; FIBRINOGEN; MUTANT PROTEIN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR; PROTHROMBIN; RECOMBINANT THROMBIN; THROMBIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BLEEDING; CONTROLLED STUDY; ENZYME SPECIFICITY; GENE MUTATION; INFLAMMATORY DISEASE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN VARIANT; THROMBOGENESIS;

EID: 79959383009     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-304915     Document Type: Article

References (50)

1. Esmon CT. Coagulation and inflammation. J Endotoxin Res. 2003;9(3):192-198. (Pubitemid 36722600)
2. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood. 2000;95(4):1113-1116. (Pubitemid 30099812)
3. Caunt M, Huang YQ, Brooks PC, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost. 2003;1(10):2097-2102.
4. Chiu YC, Fong YC, Lai CH, et al. Thrombininduced IL-6 production in human synovial fibroblasts is mediated by PAR1, phospholipase C, protein kinase C alpha, c-Src, NF-kappa B and p300 pathway. Mol Immunol. 2008;45(6):1587-1599.
5. Clark A, Weymann A, Hartman E, et al. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol. 2008;45(11):3125-3132.
6. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999;96(20): 11023-11027. (Pubitemid 29487321)
7. Myles T, Leung LL. Thrombin hydrolysis of human osteopontin is dependent on thrombin anionbinding exosites. J Biol Chem. 2008;283(26): 17789-17796.
8. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002; 99(3):1053-1059. (Pubitemid 34525570)
9. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost. 2004;30(1):63-69. (Pubitemid 38457301)
10. Arosio D, Ayala YM, Di Cera E. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C. Biochemistry. 2000; 39(27):8095-8101. (Pubitemid 30452385)
11. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature. 1995;378(6555):413-416.
12. Cantwell AM, Di Cera E. Rational design of a potent anticoagulant thrombin. J Biol Chem. 2000; 275(51):39827-39830. (Pubitemid 32064601)
13. Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem. 2002;277(31):27581-27584. (Pubitemid 34966698)
14. Gruber A, Marzec UM, Bush L, et al. Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood. 2007;109(9):3733-3740. (Pubitemid 46641722)
15. Bush LA, Nelson RW, Di Cera E. Murine thrombin lacks Na+ activation but retains high catalytic activity. J Biol Chem. 2006;281(11):7183-7188. (Pubitemid 43847484)
16. Gabazza EC, Osamu T, Yamakami T, et al. Correlation between clotting and collagen metabolism markers in rheumatoid arthritis. Thromb Haemost. 1994;71(2):199-202. (Pubitemid 24047327)
17. Ohba T, Takase Y, Ohhara M, Kasukawa R. Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor. J Rheumatol. 1996;23(9): 1505-1511. (Pubitemid 26290573)
18. Zacharski LR, Brown FE, Memoli VA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63(2):155-162.
19. Marty I, Peclat V, Kirdaite G, Salvi R, SoA, Busso N. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest. 2001;107(5): 631-640. (Pubitemid 32205184)
20. Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis. 2000;59(10): 781-787.
21. Flick MJ, Lajeunesse CM, Talmage KE, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alpha(M)beta(2) binding motif. J Clin Invest. 2007;117(11):3224-3235. (Pubitemid 350096980)
22. Yang YH, Hall P, Little CB, et al. Reduction of arthritis severity in protease-activated receptordeficient mice. Arthritis Rheum. 2005;52(4):1325- 1332. (Pubitemid 40530144)
23. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344(10):699-709. (Pubitemid 32204987)
24. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32 Suppl 1:49-60.
25. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem. 2007; 282(45):33022-33033. (Pubitemid 350159287)
26. Niessen F, Furlan-Freguia C, Fernandez JA, et al. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood. 2009;113(12):2859-2866.
27. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104(6):1740-1744. (Pubitemid 39202282)
28. Mullins ES, Kombrinck KW, Talmage KE, et al. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood. 2009;113(3):696-704.
29. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767-776.
30. Zheng X, Li W, Gu JM, et al. Effects of membrane and soluble EPCR on the hemostatic balance and endotoxemia in mice. Blood. 2007;109(3): 1003-1009. (Pubitemid 46220645)
31. Thornton S, Boivin GP, Kim KN, Finkelman FD, Hirsch R. Heterogeneous effects of IL-2 on collagen-induced arthritis. J Immunol. 2000;165(3): 1557-1563. (Pubitemid 30604592)
32. Palumbo JS, Zogg M, Talmage KE, Degen JL, Weiler H, Isermann BH. Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost. 2004;2(8):1368-1379. (Pubitemid 40186134)
33. Camerer E, Duong DN, Hamilton JR, Coughlin SR. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood. 2004;103(1):152-154. (Pubitemid 38029931)
34. Sun WY, Witte DP, Degen JL, et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998; 95(13):7597-7602. (Pubitemid 28293298)
35. Xue J, Wu Q, Westfield LA, et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci U S A. 1998;95(13):7603-7607. (Pubitemid 28293299)
36. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381(6582):516-519.
37. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101(9):1983-1991. (Pubitemid 28226118)
38. Berny MA, White TC, Tucker EI, et al. Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler Thromb Vasc Biol. 2008; 28(2):329-334. (Pubitemid 351161207)
39. Gandhi PS, Page MJ, Chen Z, Bush-Pelc L, Di Cera E. Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A. J Biol Chem. 2009;284(36):24098-24105.
40. Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34(8): 996-1005.
41. Busso N, Chobaz-Peclat V, Hamilton J, Spee P, Wagtmann N, So A. Essential role of platelet activation via protease activated receptor 4 in tissue factor-initiated inflammation. Arthritis Res Ther. 2008;10(2):R42.
42. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010; 327(5965):580-583.
43. Feistritzer C, Schuepbach RA, Mosnier LO, et al. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem. 2006;281(29): 20077-20084. (Pubitemid 44065782)
44. Guo H, Singh I, Wang Y, et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci. 2009;29(6):1119-1130.
45. Thiyagarajan M, Fernandez JA, Lane SM, Griffin JH, Zlokovic BV. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci. 2008;28(48):12788-12797.
46. Fernández JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis. 2003;30(3):271-276. (Pubitemid 36539428)
47. Shibata M, Kumar SR, Amar A, et al. Antiinflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. 2001;103(13): 1799-1805. (Pubitemid 32291419)
48. Zhong Z, Ilieva H, Hallagan L, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119(11): 3437-3449.
49. Yuda H, Adachi Y, Taguchi O, et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood. 2004;103(6):2196-2204. (Pubitemid 38326238)
50. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008; 451(7182):1076-1081. (Pubitemid 351317445)